NASDAQ:LGND

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

$79.79

+2.66 (+3.45%)

(As of 09/27/2022 12:28 PM ET)

Add

Compare

Today's Range: $79.10
▼
$81.14
50-Day Range: $77.13
▼
$107.56
52-Week Range: $72.57
▼
$169.98

Volume: 1,993 shs
Average Volume: 144,845 shs
Market Capitalization: $1.35 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $177.00

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 118.7% Upside
$177.00 Price Target
Short Interest: Bearish
5.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.19
Upright™ Environmental Score
News Sentiment: 0.13
Based on 6 Articles This Week
Insider Trading: Selling Shares
$180,000 Sold Last Quarter
Proj. Earnings Growth: 30.30%
From $1.32 to $1.72 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

131st out of 1,071 stocks

Pharmaceutical Preparations Industry

40th out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $177.00, Ligand Pharmaceuticals has a forecasted upside of 118.7% from its current price of $80.93.
Amount of Analyst Coverage
Ligand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.06% of the float of Ligand Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Ligand Pharmaceuticals has recently decreased by 3.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ligand Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ligand Pharmaceuticals does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ligand Pharmaceuticals has received a 58.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pneumococcal vaccines", "Rituximab", "Antihypertensives (C02)", "Quinolones", "Bevacizumab", and "Carfilzomib" products. See details.
Environmental Sustainability
The Environmental Impact score for Ligand Pharmaceuticals is -2.19.

2.3

News and Social Media Coverage

News Sentiment
Ligand Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Ligand Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.
MarketBeat Follows
2 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180,000.00 in company stock.
Percentage Held by Insiders
10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.87% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Ligand Pharmaceuticals are expected to grow by 30.30% in the coming year, from $1.32 to $1.72 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ligand Pharmaceuticals is -175.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ligand Pharmaceuticals is -175.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Ligand Pharmaceuticals has a PEG Ratio of 4.10. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Ligand Pharmaceuticals has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

September 25, 2022 | seekingalpha.com

Ligand Pharmaceuticals: Struggling Along

September 23, 2022 | nasdaq.com

Ligand Pharmaceuticals Becomes Oversold (LGND)

September 23, 2022 | nasdaq.com

Ligand Pharmaceuticals Becomes Oversold (LGND)

September 22, 2022 | americanbankingnews.com

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Lowered by StockNews.com

September 20, 2022 | nasdaq.com

This Insider Has Just Sold Shares In Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

September 15, 2022 | thestreet.com

Ligand Pharmaceuticals Inc Stock Downgraded (LGND)

September 14, 2022 | finance.yahoo.com

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen

September 13, 2022 | seekingalpha.com

Ligand, Sermonix breast cancer drug lasofoxifene fails to show 'statistical significance' in trial

September 13, 2022 | finance.yahoo.com

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

September 7, 2022 | finance.yahoo.com

Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

August 29, 2022 | thestreet.com

Ligand Pharmaceuticals (LGND) Shows Signs Of Being Water-Logged And Getting Wetter

August 25, 2022 | finance.yahoo.com

Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients

August 25, 2022 | nasdaq.com

Ligand : Janssen's Tecvayli Gets Conditional Approval In Europe For R/R Multiple Myeloma Treatment

August 24, 2022 | finance.yahoo.com

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

August 22, 2022 | nasdaq.com

See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity

August 12, 2022 | nasdaq.com

Analysts Just Shipped A Meaningful Upgrade To Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Estimates

August 11, 2022 | finance.yahoo.com

New Forecasts: Here's What Analysts Think The Future Holds For Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

August 8, 2022 | seekingalpha.com

Ligand Pharmaceuticals, Inc. (LGND) CEO John Higgins on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates

August 8, 2022 | finance.yahoo.com

Ligand Reports Second Quarter 2022 Financial Results

August 4, 2022 | finance.yahoo.com

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2022 | finance.yahoo.com

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have endured a 28% loss from investing in the stock five years ago

July 26, 2022 | nasdaq.com

Can Mixed Financials Have A Negative Impact on Ligand Pharmaceuticals Incorporated's 's (NASDAQ:LGND) Current Price Momentum?

July 22, 2022 | finance.yahoo.com

Ligand to Report Second Quarter Financial Results on August 8

July 5, 2022 | markets.businessinsider.com

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Company Calendar

Last Earnings: 11/09/2021
Today: 9/27/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:LGND
CUSIP: 53220K50
CIK: 886163
Web: www.ligand.com
Phone: (858) 550-7500
Fax: 858-550-1826
Employees: 154
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $177.00
High Stock Price Forecast: $310.00
Low Stock Price Forecast: $130.00
Forecasted Upside/Downside: +121.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 60.45
P/E Growth: 4.1
Net Income: $57.14 million
Net Margins: -3.13%
Pretax Margin: -5.22%
Return on Equity: 5.49%
Return on Assets: 3.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.45
Quick Ratio: 1.30

Sales & Book Value

Annual Sales: $277.13 million
Price / Sales: 4.86
Cash Flow: $8.70 per share
Price / Cash Flow: 9.17
Book Value: $49.14 per share
Price / Book: 1.62

Miscellaneous

Outstanding Shares: 16,880,000
Free Float: 15,127,000
Market Cap: $1.35 billion
Optionable: Optionable
Beta: 1.10

Key Executives

Mr. John L. Higgins (Age 52)
CEO & Exec. Director
Comp: $1.23M

Mr. Matthew W. Foehr (Age 49)
Pres & COO
Comp: $909k

Mr. Matthew E. Korenberg (Age 47)
Exec. VP of Fin. & CFO
Comp: $753.25k

Mr. Charles S. Berkman J.D. (Age 53)
Sr. VP, Gen. Counsel & Sec.
Comp: $665.83k

Simon Latimer
Head of Investor Relations

Mr. Todd Pettingill
Director of Corp. Devel.

Ms. Audrey Warfield-Graham
Sr. VP of HR

Dr. Keith Marschke
Sr. VP of Biology & Scientific Affairs

Dr. Vincent D. Antle (Age 53)
Sr. VP of Technical Operations & QA - Capitsol

Mr. Patrick Lucy
Sr. VP & CBO Protein Expression Bus.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.
What is Ligand Pharmaceuticals' stock price forecast for 2022?: 5 brokerages have issued 12 month target prices for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $130.00 to $310.00. On average, they expect the company's share price to reach $177.00 in the next twelve months. This suggests a possible upside of 129.5% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.
How have LGND shares performed in 2022?: Ligand Pharmaceuticals' stock was trading at $154.46 at the start of the year. Since then, LGND stock has decreased by 50.1% and is now trading at $77.13.
View the best growth stocks for 2022 here.
When is Ligand Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our LGND earnings forecast.
How were Ligand Pharmaceuticals' earnings last quarter?: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Tuesday, November, 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.97. The biotechnology company had revenue of $64.84 million for the quarter, compared to analysts' expectations of $60.46 million. Ligand Pharmaceuticals had a positive trailing twelve-month return on equity of 5.49% and a negative net margin of 3.13%. During the same period in the previous year, the business earned $0.71 EPS.
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?: Ligand Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share guidance of $2.40-$3.00 for the period, compared to the consensus earnings per share estimate of $2.30. The company issued revenue guidance of $169.00 million-$188.00 million, compared to the consensus revenue estimate of $162.86 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?: 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Ligand Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).
What is Ligand Pharmaceuticals' stock symbol?: Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
Who are Ligand Pharmaceuticals' major shareholders?: Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (6.42%), Macquarie Group Ltd. (4.64%), Villere ST Denis J & Co. LLC (2.94%), Stephens Investment Management Group LLC (2.69%), Chicago Capital LLC (2.66%) and abrdn plc (2.54%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr and Todd C Davis.
View institutional ownership trends.
How do I buy shares of Ligand Pharmaceuticals?: Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ligand Pharmaceuticals' stock price today?: One share of LGND stock can currently be purchased for approximately $77.13.
How much money does Ligand Pharmaceuticals make?: Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.30 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($0.46) on an earnings per share basis.
How many employees does Ligand Pharmaceuticals have?: The company employs 154 workers across the globe.
How can I contact Ligand Pharmaceuticals?: Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

Ligand Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows